SVB Leerink started coverage on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a report issued on Tuesday, Marketbeat.com reports. The firm issued an outperform rating and a $12.00 target price on the stock. A number of other brokerages have also recently weighed in on PYXS. HC Wainwright reissued a buy rating and issued […]
Pyxis Oncology (NASDAQ:PYXS) Coverage Initiated at SVB Leerink theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Pyxis Oncology (NASDAQ:PYXS) Coverage Initiated by Analysts at SVB Leerink themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) and CytoDyn (OTCMKTS:CYDY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Profitability This table compares Pyxis Oncology and CytoDyn’s […]
William Blair restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research note released on Wednesday morning, RTT News reports. Separately, Royal Bank of Canada started coverage on shares of Pyxis Oncology in a research note on Tuesday, September 5th. They issued an outperform rating and a $7.00 price […]